Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol tablets

Zhang,Yin; Xie,Yanming; Zhang,Yiying; Liu,Yan; Zhuang,Yan

doi:10.3892/br.2016.765

Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol tablets

Authors:
- Yin Zhang
- Yanming Xie
- Yiying Zhang
- Yan Liu
- Yan Zhuang
View Affiliations

Affiliations: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China, School of Statistics, Renmin University of China, Beijing 100872, P.R. China, Center of Computer Management, Navy General Hospital of PLA, Beijing 100048, P.R. China
Published online on: September 29, 2016 https://doi.org/10.3892/br.2016.765
Pages: 595-600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze the medicinal effect of Bicyclol tablets on patients with chronic hepatitis B (CHB) and concomitant mild alanine aminotransferase (ALT) elevation (40‑80 IU/l). A retrospective cohort study, which included patients from the hospital information system (HIS; established by the Chinese Academy of Medical Sciences) viral hepatitis database comprised of 18 third‑grade class A hospitals in China, was performed. Patients were divided into an exposed group (administered with Bicyclol tablets) and a non‑exposed group (no administration of Bicyclol tablets). The CHB patients that exhibited mild ALT elevation provided the curative effect analysis data set, and the patients with viral hepatitis who underwent more than two creatinine/hemoglobin/leucocyte examinations served as the safety analysis data set. The factors influencing ALT normalization rate were analyzed and the safety of Bicyclol tablets was assessed. In total, 82 pairs of patients were included in the curative effect analysis, and single factor analysis revealed that the ALT normalization rate of the exposed group was statistically significantly higher than that of the non‑exposed group (P=0.040) for patients with mild ALT elevation. After adjusting for patient age, gender, baseline ALT levels, state of illness upon admission, pattern of hospitalization, hospitalization days and drug combination, the odds ratio (95% confidence interval) of the ALT normalization rate of the exposed group was 2.156 (1.103‑4.215) when compared with the non‑exposed group. During treatment, the occurrence rates of creatinine/hemoglobin/leucocyte level abnormalities of the exposed group, which were included in the safety analysis were statistically significantly lower than those of the non‑exposed group (P<0.05). These findings indicate that Bicyclol tablets improve the ALT normalization rate of CHB patients exhibiting mild ALT elevation.

View Figures

View References

1	World Health Organization, . Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March;2015.
2	Yan YP, Su HX, Ji ZH, Shao ZJ and Pu ZS: Epidemiology of hepatitis B virus infection in China: Current status and challenges. J Clin Transl Hepatol. 2:15–22. 2014.PubMed/NCBI
3	Zheng X, Wang J and Yang D: Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol (Berl). 204:115–120. 2015. View Article : Google Scholar
4	Tang CM, Yau TO and Yu J: Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol. 20:6262–6278. 2014. View Article : Google Scholar : PubMed/NCBI
5	Manzoor S, Saalim M, Imran M, Resham S and Ashraf J: Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 21:12558–12575. 2015. View Article : Google Scholar : PubMed/NCBI
6	Nebbia G, Peppa D and Maini MK: Hepatitis B infection: Current concepts and future challenges. QJM. 105:109–113. 2012. View Article : Google Scholar : PubMed/NCBI
7	Expert Committee on Antiviral Therapy for Special Patients with Chronic Hepatitis B, . Expert Consensus on Antiviral Therapy for Special Patients with Chronic Hepatitis B: An update in 2015. J Clin Hepatol. 31:1185–1192. 2015.
8	Chinese Society of Hepatology: CMA and Society of Infectious Diseases, CMA, . Guidelines for Prevention and Treatment of Chronic Hepatitis B (2015 Edition). Chin J Exp Clin Infect Dis. 9:570–589. 2015.
9	European Association For The Study Of The Liver: EASL clinical practice guidelines, . Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al: Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016. View Article : Google Scholar : PubMed/NCBI
11	Li XN, Wu XP and Xiang TX: Characteristics of liver biopsy in chronic hepatitis B virus-infected patients with normal and minimally raised ALT. J Nanchang Univ. 51:73–76. 2011.
12	Liu GT, Li Y, Wei HL, Zhang H, Xu JY and Yu LH: Mechanism of protective action of bicyclol against CCl-induced liver injury in mice. Liver Int. 25:872–879. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wang H and Li Y: Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol. 534:194–201. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pan SY, Dong H, Yu ZL, Zhao XY, Xiang CJ, Wang H, Fong WF and Ko KM: Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 59:1657–1662. 2007. View Article : Google Scholar : PubMed/NCBI
15	Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang Z, Zhao H, Yan J and Cheng J: A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int. 6:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
16	Han Y, Shi JP, Ma AL, Xu Y, Ding X-D and Fan J-G: Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 34:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lin CL and Kao JH: Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 28:10–17. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lei J, Sockolow P, Guan P, Meng Q and Zhang J: A comparison of electronic health records at two major Peking University Hospitals in China to United States meaningful use objectives. BMC Med Inform Decis Mak. 13:962013. View Article : Google Scholar : PubMed/NCBI
19	Yu YN, Chen H and Li Y: Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. Basic Clin Pharmacol Toxicol. 104:300–305. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yao XM, Chen H and Li Y: Protective effect of bicyclol on liver injury induced by hepatic warm ischemia/reperfusion in rats. Hepatol Res. 39:833–842. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lou XE, Xu N, Yao HP and Chen Z: Bicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNA-stimulated L02 hepatocytes by inhibiting p65-NF-κB and p38-MAPK activation. Pharmazie. 65:206–212. 2010.PubMed/NCBI
22	Bao XQ and Liu GT: Involvement of HSP70 in the protection of bicyclol on apoptosis of HepG2 cells intoxicated by d-galactosamine. J Asian Nat Prod Res. 12:313–323. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yu HY, Wang BL, Zhao J, Yao XM, Gu Y and Li Y: Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology. 261:112–118. 2009. View Article : Google Scholar : PubMed/NCBI
24	Liu GT: Bicyclol: A novel drug for treating chronic viral hepatitis B and C. Med Chem. 5:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Qiang L and Pei L: Assessment of Bicyclol tablets' Effect on Viral CHB. Chin J Exp Clin Virol. 21:165–167. 2007.